Isatuximab combination therapy approved by the European Commission

On June 2, 2020, the combination of isatuximab (isa) with pomalidomide and dexamethasone (pom-dex) received approval from the European Commission for the treatment of adult patients with relapsed and refractory multiple myeloma (RRMM).¹

This decision was based on promising data from the phase III ICARIA-MM study (NCT02990338), which uncovered a significantly improved progression-free survival rate in patients receiving isa in combination with pom-dex vs pom-dex alone. In adult patients with RRMM, the triplet combination regimen significantly reduced the risk of disease progression or death by 40% compared to pom-dex alone. Read the MM Hub coverage of the ICARIA-MM trial here.

For further information on the indications of isa + pom-dex in this setting, read the European Medicines Agency’s Committee for Medicinal Products for Human Use positive opinion article on the MM Hub here.